Fermenta Biotech Limited (formerly known as DIL Limited)

CIN: L99999MH1951PLC008485

Regd. Office: A - 1501, Thane One, DIL Complex, Ghodbunder Road, Majiwade, Thane (W) - 400 610,

Maharashtra, India.

Tel.: +91-22-6798 0888 Fax.: +91-22-6798 0899

Email: info@fermentabiotech.com, Website.: www.fermentabiotech.com



Ref: F.No.:49

September 8, 2020

Corporate Relations BSE Limited, Phiroze Jeejeebhoy Towers, Dalal Street, Fort, Mumbai – 400 001

Dear Sirs,

Sub.: Disclosure of Related Party Transactions for the half-year ended March 31, 2020

Ref: Scrip Code: 506414

Pursuant to Regulation 23(9) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 and in relation to our intimation of outcome of the Board meeting dated August 28, 2020 regarding approval of the Annual Audited Financial Statements (Standalone & Consolidated) for the financial year ended March 31, 2020, please find enclosed herewith the disclosure of Related Party Transactions for the half-year ended March 31, 2020 on a consolidated basis, in the format as specified in the relevant accounting standards.

Thanking you,

Yours faithfully,

For Fermenta Biotech Limited (Formerly known as DIL Limited)

Srikant Sharma
Company Secretary & Vice President (Legal)
Membership No. FCS3617

Encl.: As above

Factory: Village Takoli, P.O. Nagwain, Dist. Mandi - 175 121, Himachal Pradesh, India.

Tel.: +91-1905-287246 / 48 / 49 Fax: +91-1905-287250

Email: info@fermentabiotech.com Website: www.fermentabiotech.com Factory: Z - 109 B & C, SEZ II, Dahej, Taluka - Vagara, Dist: Bharuch - 392 130,

Gujarat, India.

Tel.: +91-2641-291440 / 444 Email: info@fermentabiotech.com Website: www.fermentabiotech.com

Fermenta Biotech Limited (Formerly known as DIL Limited) Notes to the Consolidated financial statements for the year ended March 31, 2020



Note 48 - Related parties disclosures as per Ind AS 24

Names of the related parties and description of relationships

a) Holding Company:
DVK Investments Private Limited
b) i) Key Management Personnel

Mame of Key Management Personnel
Mr. Krishna Datla (also a person controlling the Holding Company)
Mr. Satish Varma
Mr. Sanjay Buch
Ms. Rajeshwari Datla (also relative of the Managing Director) Designation Managing Director Executive Director Non-Executive Director Non-Executive Director Ms. Anupama Datla Desai (also relative of the Managing Director) Dr. Gopakumar Nair Mr. Vinayak Hajare Executive Director Non-Executive Director Non-Executive Director Chief Executive Officer Chief Financial Officer Company Secretary Mr. Prashant Nagre Mr. Sumesh Gandhi Mr. Srikant N Sharma

c) Joint Venture Agastya Films LLP (up to December 31, 2018)

d) Associates

Associates
Health and Wellness India Private Limited
Zela Wellness Private Limited (up to November 29, 2018)
Silk Road Communications Private Limited (Associate of Holding Company)

e) Enterprises under significant influence of key management personnel or their relatives:

Magnolia FNB Private Limited Dupen Laboratories Private Limited Lacto Cosmetics (Vapi) Private limited

No.	Particulars	Holding Company	Key Management Personnel*	Enterprises under significant influence of key management personnel or their relatives	Joint ventures / associates
1	Remuneration to Directors and Key Management Personnel (including commission)*				
	Mr. Krishna Datla	- (-)	274.75 (278.52)	(-)	- (-)
	Mr. Satish Varma	- (-)	196.13 (740.11)	<u> </u>	(-)
	Ms. Anupama Datla Desai	- (-)	121.58 (621.77)	<u> </u>	(-
	Mr. Prashant Nagre	- (-)	186.32 (279.11)	<u> </u>	(-
	Mr. Sumesh Gandhi	- (-)	77.00 (77.71)	(-)	(-)
	Mr. Srikant N Sharma	<u>-</u> (-)	53.73 (48.81)	<u> </u>	- (-
	Commission to non-executive directors (excluding statutory levy)				
	Mr. Sanjay Buch	- (-)	10.01 (14.67)	<u>-</u> (-)	- (-
	Dr. Gopakumar Nair	- (-)	10.01 (14.67)	<u>-</u> (-)	<u>-</u> (-
	Ms. Rajeshwari Datla	<u>-</u> (-)	10.01		<u>-</u> (-
	Mr. Vinayak Hajare	<u>-</u> (-)	10.01		<u>-</u> (-
2	Directors sitting fees				
	Mr. Krishna Datla	- (-)	2.60 (2.80)	<u>-</u> (-)	<u>-</u> (-
	Ms. Rajeshwari Datla	- (-)	5.30 (3.30)	<u>-</u> (-)	- (-
	Mr. Satish Varma	- (-)	2.50 (3.60)	<u> </u>	<u>-</u> (-
	Mr. Sanjay Buch	<u>-</u> (-)	9.00 (6.70)	<u> </u>	<u>-</u> (-
	Mr. Vinayak Hajare	<u>-</u> (-)	6.40 (4.10)	<u> </u>	<u>-</u> (-
	Dr. Gopakumar Nair	<u>-</u> (-)	7.50 (2.80)		- (-

Fermenta Biotech Limited (Formerly known as DIL Limited) CIN:L99999MH1951PLC008485 Notes to the Consolidated financial statements for the year ended March 31, 2020



	B 1	1 '			₹ in Lakhs
No.	Particulars	Holding Company	Key Management Personnel*	Enterprises under significant influence of key management personnel or their relatives	Joint ventures / associates
3	Sale of products				
	Dupen Laboratories Private Limited	- (-)	<u> </u>	20.81 (7.08)	<u>-</u> (-)
4	Purchase of raw materials and packing materials				
	Lacto Cosmetics (Vapi) Private Limited		-	0.71	<u>-</u>
5	Processing charges	(-)	(-)	(1.24)	(-)
	Lacto Cosmetics (Vapi) Private Limited	- (-)	<u>-</u> (-)	3.69 (5.66)	<u>-</u> (-)
6	Other reimbursements received				
	Lacto Cosmetics (Vapi) Private Limited	- (-)	- (-)	1.60 (1.05)	- (-)
7	Rent income				
	DVK Investments Private Limited	0.30 (0.30)	- (-)	- (-)	- (-)
	Magnolia FNB Private Limited	- (-)	- (-)	0.30 (0.30)	- (-)
	Silk Road Communications Private Limited	- (-)	- (-)	- (-)	1.35 (1.35)
8	Provision for impairment in the value of share application money and inter corporate deposit in an associate Health and Wellness India Private Limited	<u> </u>	<u> </u>	<u> </u>	_ (223.34)
	Provision for share of loss in a joint venture in excess of cost of investment Agastya Films LLP	<u>-</u> (-)	<u> </u>	<u> </u>	- (7.05)
10	Loans taken DVK Investments Private Limited	(50.00)	<u>.</u> (-)		<u>-</u> (-)
11	Interest on loan taken DVK Investments Private Limited	4.60 (26.92)	<u> </u>	<u> </u>	<u> </u>
12	Loans repayment DVK Investments Private Limited	250.00 (-)	<u>-</u> (-)	<u>-</u> (-)	<u>-</u> (-)

⁽Figures in brackets are the corresponding figures in respect of the previous year.)

* Note: The remuneration to the key managerial personnel does not include the provisions made for gratuity and leave benefits, as they are determined on an actuarial basis for the company as a whole.

Fermenta Biotech Limited (Formerly known as DIL Limited) CIN:L99999MH1951PLC008485 Notes to the Consolidated financial statements for the year ended March 31, 2020



C) Balance outstanding as at the end of the year :

	March 31, 2020	March 31, 2019
Trade Payables Enterprises under significant influence of key management personnel or their relatives Lacto Cosmetics (Vapi) Pvt Ltd	-	1.36
 b. Trade receivables Enterprises under significant influence of key management personnel or their relatives Dupen Laboratories Pvt Ltd 	22.45	10.33
c. Other financial liabilities Key management personnel		
Mr. Krishna Datla	130.00	117.34
Mr. Satish Varma	78.00	606.69
Ms. Anupama Datla Desai	40.00	530.79
Mr. Prashant Nagre	50.05	159.61
Mr. Srikant N Sharma	_	10.98
Ms. Rajeshwari Datla	10.01	-
Dr. Gopakumar Nair	10.01	14.67
Mr.Sanjay Buch	10.01	14.67
Mr. Vinayak Hajare	10.01	_
d. Deposit from tenants Associate of Holding Company Silk Road Communications Private Limited e. Provision for diminution in the value of investment, inter-	0.20	0.20
corporate deposits and other financial assets Associate Health and Wellness India Private Limited	223.34	223.3
f. Loans to employees		
Key management personnel Mr.Prashant Nagre	27.52	26.1
Mr. Srikant N Sharma	_	1.6
g. Inter corporate deposits		
Associate Health and Wellness India Private Limited	37.00	37.00
h. Loans repayable on demand Holding company DVK Investments Private Limited	-	250.00
i. Other financial liabilities (Interest accrued but not due)		
Holding company DVK Investments Private Limited	-	38.79
j. Provision for share of loss in a joint venture in excess of cost of investment		
Joint venture Agastya Films LLP	5.97	5.9